Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS1001 + regorafenib
- Development stage
- Unknown
- Lead developer
- CStone Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CS1001 + regorafenib is an investigational combination therapy studied for the treatment of advanced or refractory solid tumors, including gastric cancer. It consists of CS1001, a monoclonal antibody targeting programmed death-ligand 1 (PD-L1), and regorafenib, an orally-administered small molecule multi-kinase inhibitor. The combination aims to provide synergistic anti-tumor effects by integrating immune checkpoint blockade and inhibition of multiple signaling pathways involved in tumor angiogenesis, metastasis, and immunity. CS1001 has shown a favorable safety and anti-tumor profile in clinical trials, while regorafenib blocks kinases such as VEGFRs, KIT, RET, RAFs, PDGFRs, FGFRs, TIE2, and CSF1R. This combination is being developed through a partnership between CStone Pharmaceuticals and Bayer[1][3][5][7][9].
- Brand names
- Stivarga
- Other names
- CS1001 plus regorafenibCS-1001 plus regorafenibCS 1001 plus regorafenibCS1001 + Stivarga
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)TEK (Tie2)CD274 (Programmed cell death protein 1 ligand 1)PDGFRB (Platelet-derived growth factor receptor beta)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on CS1001 + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS1001 + regorafenib.